CNVY vs. CBAY, VALN, BLTE, CALT, IDYA, PRTC, PNT, KNSA, INVA, and EXAI
Should you be buying Convey Health Solutions stock or one of its competitors? The main competitors of Convey Health Solutions include CymaBay Therapeutics (CBAY), Valneva (VALN), Belite Bio (BLTE), Calliditas Therapeutics AB (publ) (CALT), IDEAYA Biosciences (IDYA), PureTech Health (PRTC), POINT Biopharma Global (PNT), Kiniksa Pharmaceuticals (KNSA), Innoviva (INVA), and Exscientia (EXAI). These companies are all part of the "medical" sector.
Convey Health Solutions vs.
CymaBay Therapeutics (NASDAQ:CBAY) and Convey Health Solutions (NYSE:CNVY) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, community ranking, risk, profitability, dividends, media sentiment and valuation.
CymaBay Therapeutics received 471 more outperform votes than Convey Health Solutions when rated by MarketBeat users. Likewise, 72.85% of users gave CymaBay Therapeutics an outperform vote while only 44.44% of users gave Convey Health Solutions an outperform vote.
CymaBay Therapeutics has a net margin of 0.00% compared to Convey Health Solutions' net margin of -1.90%. Convey Health Solutions' return on equity of 0.08% beat CymaBay Therapeutics' return on equity.
Convey Health Solutions has higher revenue and earnings than CymaBay Therapeutics. Convey Health Solutions is trading at a lower price-to-earnings ratio than CymaBay Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, CymaBay Therapeutics had 19 more articles in the media than Convey Health Solutions. MarketBeat recorded 19 mentions for CymaBay Therapeutics and 0 mentions for Convey Health Solutions. CymaBay Therapeutics' average media sentiment score of 0.47 beat Convey Health Solutions' score of 0.00 indicating that CymaBay Therapeutics is being referred to more favorably in the media.
73.5% of CymaBay Therapeutics shares are owned by institutional investors. Comparatively, 85.3% of Convey Health Solutions shares are owned by institutional investors. 5.6% of CymaBay Therapeutics shares are owned by insiders. Comparatively, 6.2% of Convey Health Solutions shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
CymaBay Therapeutics has a beta of 0.29, meaning that its share price is 71% less volatile than the S&P 500. Comparatively, Convey Health Solutions has a beta of -0.3, meaning that its share price is 130% less volatile than the S&P 500.
CymaBay Therapeutics currently has a consensus price target of $13.50, indicating a potential upside of 53.58%. Convey Health Solutions has a consensus price target of $11.40, indicating a potential upside of 8.47%. Given CymaBay Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe CymaBay Therapeutics is more favorable than Convey Health Solutions.
Summary
CymaBay Therapeutics beats Convey Health Solutions on 11 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CNVY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Convey Health Solutions Competitors List
